Hong Kong Renewable Energy Stock News

Ascletis Pharma Inc. announced the selection of ASC36, a once-monthly subcutaneously administered amylin receptor agonist, as its next clinical development candidate for obesity, with an anticipated US FDA Investigational New Drug Application submission in the second quarter of 2026. This candidate was discovered and optimized using Ascletis' proprietary artificial intelligence-assisted drug discovery and ultra-long-acting platform technologies, emphasizing the company's innovative approach...

BYD (SEHK:1211) reported five-year annualized earnings growth of 47.1%, while more recent annual growth sits at 13.1%. With earnings projected to climb 18.84% per year and revenue expected to increase by 12.4% annually, both outpacing Hong Kong market averages, investors are watching these growth metrics closely. Net profit margins came in at 4.6%, down a touch from last year’s 5%, reflecting ongoing pressure but leaving room for optimism about forward momentum. See our full analysis for...

AIA Group Limited recently reported a record 25% rise in its third-quarter 2025 value of new business, with double-digit growth led by Hong Kong, Mainland China, ASEAN, and India. This result was driven by a record agency value of new business and an 18% increase in recruitment, reflecting the company's strong distribution capabilities in Asian markets. We'll examine how AIA Group's record growth in new business value influences its investment outlook and long-term earnings narrative. These...

Innovent Biologics recently reported third quarter 2025 product revenue exceeding RMB 3.3 billion, achieving around 40% year-on-year growth driven by both oncology and newly launched biomedicine therapies, including mazdutide and SINTBILO®. The company also announced positive Phase 3 results for mazdutide, showing it surpassed semaglutide in both glycemic and weight reduction outcomes for Chinese patients with type 2 diabetes and obesity, highlighting a potential new-generation treatment...

Weichai Power (SEHK:2338) reported another year of earnings growth, with net profit margins improving to 5.3% from 5.1% and annual earnings rising by 8.8%, outpacing its five-year average of 5.6% a year. Looking ahead, forecasts point to annual earnings growth of 10.92% and revenue gains of 5.8% per year. Trading at a price-to-earnings ratio of 10.6x, which stands below both the peer average and industry levels, the stock offers investors a margin story supported by solid profitability...

CSPC Pharmaceutical Group (SEHK:1093) has just made headlines with two R&D milestones. Its JSKN003 therapy gained Breakthrough Therapy Designation for advanced colorectal cancer, and SYH2061 secured clearance for clinical trials in China. See our latest analysis for CSPC Pharmaceutical Group. After a stellar run earlier this year, CSPC Pharmaceutical Group’s share price recently cooled off, dropping 18.4% over the past month and 22.7% in the last 90 days. Still, its year-to-date share price...

Everest Medicines (SEHK:1952) has secured exclusive rights to develop and commercialize VIS-101, a promising bifunctional treatment for eye conditions like wet AMD, across Greater China and parts of Asia. This strategic move underscores the company’s ambitions in ophthalmology and signals potential growth ahead. See our latest analysis for Everest Medicines. Everest Medicines’ exclusive VIS-101 deal adds momentum to a year already marked by strong long-term performance. The company posted an...

Akeso (SEHK:9926) was in the spotlight after recently published Phase III HARMONi-6 study results showed its bispecific antibody, ivonescimab, plus chemotherapy significantly improved progression-free survival in advanced squamous NSCLC compared to current treatments. See our latest analysis for Akeso. Akeso’s big clinical win comes after a year of remarkable momentum, with a year-to-date share price return of 93.5% and a 66.3% total shareholder return over the past twelve months. Excitement...

Key Insights Significant insider control over VCREDIT Holdings implies vested interests in company growth 51% of the...

China Gingko Education Group Company Limited ( HKG:1851 ) shareholders would be excited to see that the share price has...

Key Insights The projected fair value for CMON is HK$0.044 based on 2 Stage Free Cash Flow to Equity With HK$0.04 share...

Unfortunately for some shareholders, the Shandong Hi-Speed Holdings Group Limited ( HKG:412 ) share price has dived 54...

Key Insights Man Wah Holdings' significant insider ownership suggests inherent interests in company's expansion Man Li...

Following the solid earnings report from China National Building Material Company Limited ( HKG:3323 ), the market...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

It is hard to get excited after looking at China Medical System Holdings' (HKG:867) recent performance, when its stock...

Despite the fact that China Dredging Environment Protection Holdings Limited (HKG:871) stock rose 11% last week...

Yoho Group Holdings Limited ( HKG:2347 ) shareholders won't be pleased to see that the share price has had a very rough...

Most readers would already be aware that Global New Material International Holdings' (HKG:6616) stock increased...

Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish...

The Mingfa Group (International) Company Limited ( HKG:846 ) share price has fared very poorly over the last month...

Key Insights Hengan International Group's significant insider ownership suggests inherent interests in company's...

Key Insights The considerable ownership by public companies in Wynn Macau indicates that they collectively have a...

New World Development (SEHK:17) shares have seen some movement recently, prompting investors to keep an eye on how the stock is navigating current market dynamics. Its activity this month stands out as market watchers examine future prospects. See our latest analysis for New World Development. New World Development’s shares have been on a rollercoaster this year, with short-term gains giving way to recent losses. After a sharp 90-day share price return of 10.45% and a strong year-to-date...